Evaluation of a Three Rapid Test Algorithm for the Diagnosis of HIV Infection at Point-of-Care Rapid Testing Facilities: Strategy 4 Data Needs. R. Boromisa1, J. Schwendemann1, M. Parker1, T. Sullivan1, M. San Antonio-Gaddy2, A. Richardson-Moore2 NEW - PowerPoint PPT Presentation

Loading...

PPT – Evaluation of a Three Rapid Test Algorithm for the Diagnosis of HIV Infection at Point-of-Care Rapid Testing Facilities: Strategy 4 Data Needs. R. Boromisa1, J. Schwendemann1, M. Parker1, T. Sullivan1, M. San Antonio-Gaddy2, A. Richardson-Moore2 NEW PowerPoint presentation | free to download - id: 79864d-ZjFkM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Evaluation of a Three Rapid Test Algorithm for the Diagnosis of HIV Infection at Point-of-Care Rapid Testing Facilities: Strategy 4 Data Needs. R. Boromisa1, J. Schwendemann1, M. Parker1, T. Sullivan1, M. San Antonio-Gaddy2, A. Richardson-Moore2 NEW

Description:

Evaluation of a Three Rapid Test Algorithm for the Diagnosis of HIV Infection at Point-of-Care Rapid Testing Facilities: Strategy 4 Data Needs. – PowerPoint PPT presentation

Number of Views:24
Avg rating:3.0/5.0

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Evaluation of a Three Rapid Test Algorithm for the Diagnosis of HIV Infection at Point-of-Care Rapid Testing Facilities: Strategy 4 Data Needs. R. Boromisa1, J. Schwendemann1, M. Parker1, T. Sullivan1, M. San Antonio-Gaddy2, A. Richardson-Moore2 NEW


1
Evaluation of a Three Rapid Test Algorithm for
the Diagnosis of HIV Infection at Point-of-Care
Rapid Testing Facilities Strategy 4 Data
Needs.R. Boromisa1, J. Schwendemann1, M.
Parker1, T. Sullivan1, M. San Antonio-Gaddy2, A.
Richardson-Moore2NEW YORK STATE DEPARTMENT OF
HEALTHWADSWORTH CENTER 1AIDS INSTITUTE
2ALBANY, NY
2
(No Transcript)
3
(No Transcript)
4
Description of test data for 11 A1/A2 Western
blot indeterminate specimens.
Specimen number EIA s/co Multispot result (A2) WB Band pattern HIV-1 RNA
061086002 QNS 4,1,0,0 p24,p51,gp160 Positive
061806001 9.92 4,4,2,0 p24,p51,p66,gp160 Positive
061816003 9.92 4,4,2,0 gp41,gp 120/160 Positive
062656003 9.92 4,4,3,0 p17,p24,p31,p51,p66,gp120/160 Positive
063356003 9.92 4,4,2,0 p17,p24,p66,gp120/160 Positive
072606003 10.07 4,2,4,0 p24,p51 Positive
072116003 10.89 4,0,2,0 p17,p24 Positive
071866006 10.10 4,0,3,0 p24,p31,p51,p55,p66,gp160 Positive
071986003 9.45 4,0,4,0 p24,p31,gp41,p51,p66,gp160 Invalid
063496002 9.27 4,4,2,0 p17,p24,p66,gp120/160 Invalid
072396003 10.04 4,4,0,0 p24,p55,gp120/160 QNS
Weakly reactive WB band
5
Description of test data for 3 A1/A2 Western
blot negative specimens.
Specimen number EIA s/co Multispot result (A2) WB band pattern HIV-1 RNA
072156004 10.27 4,1,1,0 No bands Positive
070226001 lt1 4,0,3,0 No bands Negative
072706001 lt1 4,0,1,0 No bands Negative
6
Description of test data for 3 A1/A2-/A3
specimens.
Specimen number EIA s/co Multispot result WB band pattern HIV-1 RNA
072196004 lt1 4,0,0,0 No bands Negative
070386001 lt1 4,0,0,0 No bands Negative
070876001 1.015 4,0,0,0 No bands Negative
7
Details of 6 A1/A2-/A3- specimens that were EIA
reactive.
Specimen Number EIA s/co WB result HIV-1 RNA
060816005 8.629 Negative Negative
062296001 2.957 Negative Negative
062796003 1.718 Negative Negative
062916003 2.172 Negative Negative
070226002 3.802 Negative Negative
063496003 9.924 Negative Invalid
8
Data Needs for Strategy 4 Questions 1 - 6
  • 1) Number and percentage of false positive
    A1/A2 results in truly uninfected persons, as
    detected by laboratory-based supplemental
    testing.
  • Only 2 of 11 A1/A2 WB indeterminate or
    negative specimens that produced valid HIV-1 RNA
    results were negative (2/136, 1.5).

9
Data Needs for Strategy 4 (continued)
  • 2) Number and percentage of persons referred to
    medical care on presumptive positive rapid test
    results who are actually in medical care within
    six months of receiving the results.
  • In 2006-2007, there were a total of 148
    confirmed positive clients. There were 106
    clients (71.6) that accepted referrals for
    medical care but only 77 (72.6) reached their
    referrals.

10
Data Needs for Strategy 4 (continued)
  • 3) Number and percentage of specimens with
    negative rapid tests (A1-) that were determined
    to be false negative results by acute infection
    screening and the impact of using risk-based
    criteria for acute infection screening.
  • This study did not test A1- specimens for
    acute HIV infection screening. The impact of
    using risk-based criteria for acute infection
    screening has not been determined.

11
Data Needs for Strategy 4 (continued)
  • 4) Number and percentage of specimens with
    presumptive positive rapid tests results that
    have false negative results on the A2 test as
    determined by further clinical evaluation.
  • None of the 38 A2- specimens were false
    negative. The 3 A2- specimens (7.9) that were
    weekly reactive on the A3 rapid test were HIV-1
    RNA negative.

12
Data Needs for Strategy 4 (continued)
  • 5) Number and percentage of specimens with
    inconclusive rapid test results for one or more
    of the following
  • False positive A1 results
  • There were 40 false positive A1 specimens
    (40/174, 23.0) identified in this study 35
    A2-/A3-/WB-, 3 A2-/A3/WB-/RNA-, and 2
    A2/WB-/RNA-.
  • False negative A2 and A3 results
  • None of the 35 A2-/A3- specimens were thought
    to be false negatives even though HIV-1 RNA was
    not performed on EIA- specimens. All 35 specimens
    were WB negative.

13
Data Needs for Strategy 4 (continued)
  • 6) For persons with inconclusive rapid test
    results (A1/A2-/A3-)
  • Number and percentage of clients that are
    uninfected
  • There were 40 clients that were determined to
    be uninfected 35 A2-/A3-/WB-, 3 A2-/A3/WB-/RNA-
    and 2 A2/WB-/RNA- (40/174, 23.0).
  • Rates of receipt of laboratory results
  • In 2006-2007, 110 of 148 clients (74.3)
    received their confirmed test result.

14
Data Needs for Strategy 4 (continued)
6) For persons with inconclusive rapid test
results (A1/A2-/A3-)
(continued)
  • Whether a change in the message a client receives
    from a counselor influences client return rates
    to receive their laboratory test results
  • We cannot say with confidence whether a
    counseling message changes the return rate for
    clients since so many other variables, including
    whether they already knew their HIV positive
    status or they went directly to a medical
    provider instead of returning to the program site.

15
Description of Multispot (BioRad) HIV-1/HIV-2
Reactive Control Spot and Test Spots.
1. Procedural control Anti-human IgG (goat) 2.
HIV-2 Peptide Peptide representing the HIV-2
virus gp36 3. Recombinant HIV-1 Recombinant
gp41 (gp41rDNA) 4. HIV-1 Peptide Peptide
representing the HIV-1 virus gp41
About PowerShow.com